Background: Alzheimer’s disease (AD) is the most common cause of dementia. It is a multifactorial degenerative disease pathologically characterized by intracellular neurofibrillary tangles and extracellular deposition of amyloid. An early hemostatic dysregulation is also present and contributes to an increment in clot formation, leading to hypoperfusion, blood brain barrier disruption and neuronal loss. The detection of this prothrombotic state is of the upmost importance in diagnostic approaches to identify AD patients who would benefit from anticoagulation. Method: The aim of this project is to use an in vivo nanotracer for the detection of brain thrombi in an AD mouse model by fast pre-targeted positron emission tomography (PET) imaging. For that purpose, AD animals and their wild-type littermates were intravenously injected with the antiplatelet antibody against CD41 conjugated with transcyclooctene (TCO-antiCD41). Twenty-four hours later, [68Ga]core-doped iron oxide nanoparticles (NP) functionalized with tetrazine (TZ) were intravenously administered. TCO and TZ produce a rapid in vivo reaction by means of bioorthogonal chemistry, allowing to non-invasively evaluate platelets’ levels by PET. Two hours after [68Ga]NP-TZ injection, a static PET study of each mouse was acquired with a scanner for small animals (nanoScan® PET/CT, Mediso, USA). Finally, biodistribution assays of different organs after the PET study were performed. All PET images were analyzed by regions of interest and voxel-wise analyses. Conclusions: Our results provide a neuroimaging strategy to diagnose the prothrombotic state towards the personalization of anticoagulation treatment in AD patients.